Syra Health Corp Listed Resale
Proposed symbol SYRA on OTCQB · First filed Sep 14, 2026 · CIK 1922335
Effective prospectus: S-1 Sep 14, 2026 (0001493152-26-042591) · terms available
“This prospectus relates to the resale by the Selling Stockholders identified in this prospectus under the caption "Selling Stockholders," from time to time, of up to an aggregate of 3,171,100 shares of Common Stock. We are not selling any shares of Common Stock under this prospectus, and we will not receive any proceeds from the sale of shares of Common Stock offered hereby by the Selling Stockholders, although we may receive cash from the exercise of the Warrants.”
What the company does
Syra Health Corp. is a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. The company leverages scientific and healthcare expertise to create patient-centric solutions across behavioral and mental health, population health, digital health, health education, and healthcare workforce, serving payers, providers, life sciences organizations, academic institutions, and the government. Its offerings focus on prevention, improved access, and affordable care, and include products such as Syrenity, a mental health application designed for preventative care and interventions.
Use of proceeds
The company will not receive any proceeds from the sale of shares by the Selling Stockholders. It will, however, receive proceeds from the cash exercise of the Series B Warrants, with 3,171,100 warrants outstanding each exercisable for one share of Class A common stock at $0.64 per share, potentially yielding aggregate gross proceeds of approximately $2,029,504. Any such net proceeds are intended to be used for marketing and sales, application development, research and development, and general corporate purposes, including working capital, operating expenses, and capital expenditures.
Underwriters
The completed effective-prospectus read stated no underwriters.
Extracted from S-1 0001493152-26-042591, filed Sep 14, 2026 and verified against that filing text.
Key risk factors
The completed effective-prospectus read stated no risk factors.
Financials before the first trade
| Fiscal Year | Revenue | Growth YoY | Gross Profit | Gross Margin | Operating Income | Net Income | Operating CF | Cash | Total Assets |
|---|---|---|---|---|---|---|---|---|---|
|
FY 2025
ended 2025-12-31
|
$7.23M | -9.5% | $2.49M | 34.4% | -$904.32K | -$896.33K | -$447.75K | $1.61M | $2.77M |
|
FY 2024
ended 2024-12-31
|
$7.98M | +44.7% | $1.65M | 20.7% | -$3.76M | -$3.76M | -$2.93M | $2.4M | $3.68M |
|
FY 2023
ended 2023-12-31
|
$5.52M | -1.8% | $1.41M | 25.6% | -$2.89M | -$2.94M | -$2.76M | $3.28M | $4.92M |
|
FY 2022
ended 2022-12-31
|
$5.62M | — | $1.06M | 18.9% | -$2.09M | -$2.12M | -$2.24M | $3344 | $2.32M |
From the company's own XBRL-tagged financial statements (SEC companyfacts), full fiscal years only. Growth and margins are computed from the stated figures.
Filing history
| Filed | Form | Accession | |
|---|---|---|---|
| 2026-09-14 | S-1 | 0001493152-26-042591 | View on EDGAR |
Source quotes
Shares offered: “This prospectus relates to the resale by the Selling Stockholders identified in this prospectus under the caption "Selling Stockholders," from time to time, of up to an aggregate of 3,171,100 shares of Common Stock.”